Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan

Urologia Internationalis

Volumn 71, Issue 3, 2003, Pages 262-270

  Tsai, Yuh Shyan ^a   Tzai, Tzong Shin ^a   Chow, Nan Hua ^a   Yang, Wen Horng ^a   Tong, Yat Ching ^a   Lin, Johnny S N ^a   Chang, Chien Chen ^a   Cheng, Hong Lin ^a   Lin, Yung Ming ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Bladder neoplasm; ErbB 2 receptor; HER 2 neu; p53; Prognosis

Indexed keywords

PARAFFIN; PROTEIN P53;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STAINING; STATISTICAL SIGNIFICANCE; TAIWAN; TREATMENT OUTCOME; URINARY DIVERSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TAIWAN; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0141649419     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072676     Document Type: Article

References (37)

1. Messing EM, Catalona W: Urothelial tumors of the urinary tract; in Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds): Campbell's Urology, ed 3. Philadelphia, Saunders, 1998, pp 2348-2349.
2. Crawford ED, Das S, Smith JA Jr: Preoperative radiation therapy in the treatment of bladder cancer. Urol Clin North Am 1987;14:781-787.
3. Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992;10:1066-1073.
4. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 1989;64:2448-2458.
5. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-1264.
6. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG: p53 and treatment of bladder cancer. Nature 1997;385:123-125.
7. Keegan PE, Lunec J, Neal DE: p53 and p53-regulated genes in bladder cancer. Br J Urol 1998;82:710-720.
8. Moriyama M, Akiyama T, Yamamoto T, Kawamoto T, Kato T, Sato K, Watanuki T, Hikage T, Katsuta N, Mori S: Expression of c-erb B-2 gene product in urinary bladder cancer. J Urol 1991;145:423-427.
9. Lipponen PK: Expression of c-erb B-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer 1993;29A:749-753.
10. Lee SE, Chow NH, Chi YC, Tzai TS, Yang WH, Lin SN: Expression of c-erbB-2 protein in normal and neoplastic urothelium: Lack of adverse prognostic effect in human urinary bladder cancer. Anticancer Res 1994;114:1317-1324.
11. Miyamoto H, Kubota Y, Noguchi S, Takase K, Matsuzaki J, Moriyama M, Takebayashi S, Kitamura H, Hosaka M: c-erb B-2 gene amplification as a prognostic marker in human bladder cancer. Urology 2000;55:679-683.
12. Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167.
13. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001;8:11-31.
14. Lu Z, Jiang G, Blume-Jensen P, Hunter T: Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 2001;21:4016-4031.
15. Bullock AN, Fersht AR: Rescuing the function of mutant p53. Nat Rev Cancer 2001;1:68-76.
16. Zhou BP, Liao Y, Xia Y, Zou Y, Spohn B, Hung MC:HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001;3:973-982.
17. Huang GC, Hobbs S, Walton M, Epstein RJ: Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells. Br J Cancer 2002;86:1104-1109.
18. Chang FL, Lai MD: The relationship between p53 status and anticancer drugs-induced apoptosis in nine human bladder cancer cell lines. Anticancer Res 2000;20:351-356.
19. Su SJ, Lai MD, Yeh TM, Chow NH: Overexpression of HER-2/neu enhances the sensitivity of human bladder cancer cells to urinary isoflavones. Eur J Cancer 2001;27:1413-1418.
20. Chen C, Chauang YC, Lin TM, Wu HY: Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: High-arsenic artesian well water and cancers. Cancer Res 1985;45:5895-5899.
21. Zhao CQ, Young MR, Diwan BA, Coogan TP: Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 1997;94:10907-10912.
22. Tzai TS, Chow NH, Lin JSN, Yang WH, Tong YC: The expression of p53 and Bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. Anticancer Res 1998;18: 4717-4722.
23. Kraggerud SM, Jacobsen KD, Berner A, Stokke T, Holm R, Smedshammer L, Borresen-Dale AL, Fossa SD: A comparison of different modes for detection of p53 protein accumulation. Pathol Res Pract 1997;193:471-478.
24. Clausen OP, Lothe RA, Borresen-Dale AL, De Angelis P, Chen Y, Rognum TO, Meling GI: Association of p53 accumulation with TP53 mutations, loss of heterozygosity at 17p13, and DNA ploidy status in 273 colorectal carcinomas. Diagn Mol Pathol 1998;7:215-223.
25. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS: Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001;7:1957-1962.
26. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001;19:666-675.
27. Lerner SP, Skinner DG, Lieskovsky G, Boyd SD, Groshen SL, Ziogas A, Skinner E, Nichols P, Hopwood B: The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases. J Urol 1993;149:758-765.
28. Cheng J, Huang H, Zhang ZT, Shapiro E, Pellicer A, Sun TT, Wu XR: Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res 2002;62:4157-4163.
29. Jarvinen TA, Liu ET: Effects of HER-2/neu on chemosensitivity of tumor cells. Drug Resist Updat 2000;3:319-324.
30. Sandri MI, Isaacs RJ, Ongkeko WM, Harris AL, Hickson ID, Broggini M, Vikhanskaya F: p53 regulates the minimal promoter of the human topoisomerase IIα gene. Nucleic Acids Res 1996;24:4464-4470.
31. Kwon Y, Shin BS, Chung IK: The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIα by enhancing the rate of ATP hydrolysis. J Biol Chem 2000;275:18503-18510.
32. Kielb SJ, Shah NL, Rubin MA, Sanda MG: Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer. J Urol 2001;166:482-487.
33. Chang FL, Lai MD: Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells. J Urol 2001;166:304-310.
34. Bonnefoi H, Ducraux A, Movarekhi S, Pelte MF, Bongard S, Lurati E, Iggo R: p53 as a potential predictive factor of response to chemotherapy: Feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients. Br J Cancer 2002;86:750-755.
35. Weller M: Predicting response to cancer chemotherapy: The role of p53. Cell Tissue Res 1998;292:435-445.
36. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP: Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 1997;94:10907-10912.
37. Vogt BL, Rossman TG: Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts - A possible mechanism for arsenite's comutagenicity. Mutat Res 2001;478:159-168.